Preparation, characterization, and evaluation of gatifloxacin loaded solid lipid nanoparticles as colloidal ocular drug delivery system

Journal of Drug Targeting

Volumn 18, Issue 3, 2010, Pages 191-204

  Kalam, Mohd Abul ^a   Sultana, Yasmin ^a   Ali, Asgar ^a   Aqil, Mohd ^a   Mishra, Anil K ^b   Chuttani, Krishna ^b  

^a HAMDARD UNIVERSITY   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

Compritol 888 ATO; Corneal hydration; Crystallinity index; Excised goat cornea; Polymorphic transitions; Solid lipid nanoparticles; Stearic acid

Indexed keywords

ALCOHOL; EYE DROPS; GATIFLOXACIN; GLYCEROL BEHENATE; POLOXAMER; SOLID LIPID NANOPARTICLE; STEARIC ACID; SURFACTANT; TAUROCHOLIC ACID;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA EDEMA; CORNEA PERMEABILITY; CRYSTAL; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; EX VIVO STUDY; IN VITRO STUDY; INFRARED SPECTROSCOPY; MICROCRYSTALLINE SUSPENSION; MICROEMULSION; NANOANALYSIS; NANOFABRICATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; X RAY DIFFRACTION; ZETA POTENTIAL;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFECTIVE AGENTS; CHEMISTRY, PHARMACEUTICAL; COLLOIDS; CORNEA; CRYSTALLIZATION; DRUG STABILITY; DRUG STORAGE; EMULSIONS; EXCIPIENTS; FLUOROQUINOLONES; GOATS; LIPIDS; NANOPARTICLES; PARTICLE SIZE; PERMEABILITY; RHEOLOGY; SURFACE-ACTIVE AGENTS;

EID: 77949419485     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611860903338462     Document Type: Article

References (33)

1. Attama AA, Reichl S, Müller-Goymann CC. (2008). Diclofenac sodium delivery to the eye: in vitro evaluation of novel solid lipid nanoparticle formulation using human cornea construct. Int J Pharm, 355: 307-313.
2. Attama AA, Schicke BC, Müller-Goymann CC. (2006). Further characterization of theobroma oil-beeswax admixtures as lipid matrices for improved drug delivery systems. Eur J Pharm Biopharm, 64: 294-306
3. Attama AA, Schicke BC, Paepenmüller T, Müller-Goymann CC. (2007). Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization. Eur J Pharm Biopharm, 67: 48-57.
4. Bristol Myers Squibb Company. New Drug Application for Tequin (Gatifloxacin Tablets and Injections). Environmental Assessment. Center for Drug Evaluation and Research, Website. 2001, Accessed May 31, 2006.
5. Bunjes H, Westesen K, Koch MHJ. (1996). Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int J Pharm, 129: 159-173.
6. Cavalli R, Caputo O, Carlotti ME, Trotta M, Scarnecchia C, Gasco MR. (1997). Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int J Pharm, 148: 47-54.
7. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. (2002). Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm, 238: 241-245.
8. Dingler A, Gohla S. (2002). Production of solid lipid nanoparticles (SLN): scaling up feasibilities. J Microencapsul, 19: 11-16.
9. Freitas C, Müller RH. (1999). Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm, 47: 125-132.
10. Friedrich I, Reichl S, Müller-Goymann CC. (2005). Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS). Int J Pharm, 305: 167-175.
11. Gan L, Gan Y, Zhu C, Zhang X, Zhu J. (2009). Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results. Int J Pharm, 365: 143-149.
12. Gasco MR. (1993). Method for producing solid lipid microspheres having a narrow size distribution, US Patent 5 250 236.
13. Gokce EH, Sandri G, Bonferoni MC, Rossi S, Ferrari F, Güneri T, Caramella C. (2008). Cyclosporine A loaded SLNs: evaluation of cellular uptake and corneal cytotoxicity. Int J Pharm, 364: 76-86.
14. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. (2005). Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B Biointerfaces, 45: 167-173.
15. Kalam MA, Sultana Y, Samad A, Ali A, Aqil M, Sharma M, Mishra AK. (2008). Gelrite-based in-vitro gelation ophthalmic drug delivery system of gatifloxacin. J Disp Sci Tech, 29: 89-96.
16. Liu J, Gong T, Wang C, Zhong Z, Zhang Z. (2007). Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Int J Pharm, 340: 153-162.
17. Maurice DM. (1970). The transparency of the corneal stroma. Vision Res, 10: 107-108.
18. Mehnert W, zur-Muhlen A, Dingler A, Weyhers H, Muller RH. (1997). Solid Lipid Nanoparticles (SLN)-ein neuartiger Wirkstoff-Carrier fur Kosmetika und Pharmazeutika. II. Wirkstoff-Inkorporation, Freisetzung und Sterilizierbarkeit. Pharm Ind, (59): 511-514.
19. Motwani SK, Chopra S, Talegaonkar S, Kohli K, Ahmad FJ, Khar RK. (2008). Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm, 68: 513-525.
20. Muller RH, Mader K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm, 50: 161-177.
21. Muller RH, Mehnert W, Lucks JS, Schwarz C, zur-Muhlen A, Weyhers H, Freitas C, Ruhl D. (1995). Solid lipid nanoparticles (SLN)-an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm, 41: 62-69.
22. Muller RH, Runge SA, Ravelli V, Thunemann AF, Mehnert W, Souto EB. (2008). Cyclosporine-loaded solid lipid nanoparticles (SLN): Drug-lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm, 68: 535-544.
23. Muller-Goymann CC. (2004). Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharm, 58: 343-356.
24. Niddam-Hildesheim V, Wizel S, Sterimbaum G. (2004). United States Patent. Publication number. US 2004/0192700 A1. Publication date: Sep. 30, 2004.
25. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. (2002). Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci, 16: 53-61.
26. Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. (2002). Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials, 23: 3247-3255.
27. Pijls RT, Sonderkamp T, Daube GW, Krebber R, Hanssen HHL, Nuijts RMMA, Koole LH. (2005). Studies on a new device for drug delivery to the eye. Eur J Pharm Biopharm, 59: 283-288.
28. Rathore MS, Majumdar DK. (2006). Effect of formulation factors on in-vitro transcorneal permeation of gatifloxacin from aqueous drops. AAPS Pharm Sci Tech, 7: E1-E6.
29. Shah AK, Date AA, Joshi MD, Patravale VA. 2007. Solid lipid nanoparticles (SLN) of tretinoin: Potential in topical delivery. Int J Pharm, 345: 163-171.
30. Van Ooteghem MM. (1993). In Edman P. (ed.), Biopharmaceutics of Ocular Drug Delivery (pp. 27-41) Boca Raton: CRC Press.
31. Westesen K, Bunjes H, Koch MHJ. (1997). Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release, 48: 223-236.
32. Wissing SA, Kayser O, Muller RH. (2004). Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev, 56: 1257-1272.
33. Yamaguchi M, Yasueda S, Isowaki A, Yamamoto M, Kimura M, Inada K, Ohtori A. (2005). Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, difluprednate. Int J Pharm, 301: 121-128.